Massachusetts Financial Services Co. MA Purchases 107,348 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Massachusetts Financial Services Co. MA grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,267,375 shares of the biopharmaceutical company’s stock after buying an additional 107,348 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.09% of Amicus Therapeutics worth $30,779,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP raised its stake in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Norges Bank acquired a new stake in shares of Amicus Therapeutics in the fourth quarter valued at approximately $29,033,000. Trexquant Investment LP boosted its stake in shares of Amicus Therapeutics by 101.6% in the fourth quarter. Trexquant Investment LP now owns 966,049 shares of the biopharmaceutical company’s stock valued at $9,100,000 after buying an additional 486,827 shares during the period. Vanguard Group Inc. grew its position in Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock worth $275,619,000 after buying an additional 458,143 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in Amicus Therapeutics by 41.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after acquiring an additional 398,942 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on FOLD. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Trading Down 6.3 %

NASDAQ FOLD opened at $7.50 on Monday. Amicus Therapeutics, Inc. has a twelve month low of $7.39 and a twelve month high of $12.65. The business’s fifty day moving average is $9.12 and its 200 day moving average is $9.84. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.